LUCAS DA SILVA FAUSTINO
ANA PAULA DUARTE DE SOUZA
Bibliography: 1989-1992 Doktor der Naturwissenschaften (Ph.D.), Microbiology, Eberhard-Karls-Universität, Tübingen, Germany 1992-1995 Post-Doctoral Fellow, Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Portland, OR 1995-1996 Research Assistant Professor, Dept. Mol. Microbiol. & Immunol., OHSU, Portland, OR 1996-2001 Assistant Professor, Dept. Med. Microbiol. & Immunol., Texas A&M University SHSC, College Station, TX 2001-2005 Associate Professor, Dept. Med. Microbiol. & Immunol., Texas A&M University SHSC, College Station, TX 2005-present Professor, Dept. Med. Microbiol. & Immunol., University of California at Davis, Davis, CA, 2010 Elected to Fellowship in the American Academy of Microbiology 2020 Elected to Fellowship in the German National Academy of Sciences (Leopoldina)
Professor Pollard is Director of the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford and an honorary consultant paediatrician at Oxford Children’s Hospital and Fellow of St Cross College. He received a knighthood in the Queen’s Birthday Honours in 2021 for services to Public Health, especially in the pandemic. His research includes the design, development and clinical evaluation of vaccines including those for typhoid, meningococcus, Haemophilus influenzae type b, pneumococcus, plague, pertussis, influenza, rabies, coronavirus and Ebola, and leads studies using a human challenge model of paratyphoid and typhoid. He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal and leads a project on burden and transmission of typhoid in Nepal, Bangladesh and Malawi, and co-leads typhoid vaccine impact studies at these sites. He was the chief investigator for the clinical trials of the Oxford-AstraZeneca vaccine in 2020 in 24,000 participants in UK, South Africa and Brazil, which led to authorisation of the vaccine for use in more than 170 countries with over 550million doses distributed by July 2021. He has supervised 37 PhD students and his publications includes over 500 manuscripts and books on various topics in paediatrics and infectious diseases. He chairs the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation, is a member of WHO’s Strategic Advisory Group of Experts. He chaired the European Medicine’s Agency scientific advisory group on vaccines for 8 years until 2020. He received the “Science Honor and Truth Award” of the Instituto de Patologia en la Altura in La Paz, Bolivia in 2002, the Bill Marshall Award of the European Society for Paediatric Infectious Disease (ESPID) in 2013, the ESPID Distinguished Award for Education and Communication in 2015 and the Rosén von Rosenstein medal in 2019 awarded by the Swedish Paediatric Society and the Swedish Society of Medicine. He was elected to the Academy of Medical Sciences in 2016 and is an NIHR Senior Investigator. He received the Oxford University Vice Chancellor’s Innovation Award in 2020 for his work on typhoid vaccines. He made the first British ascent of Jaonli (6632m) in 1988 and Chamlang in 1991 (7309m) and was the Deputy leader of the successful 1994 British Medical Everest Expedition.
ANGELICA THOMAZ VIEIRA
CLAUDIA IDA BRODSKYN
Endereço para acessar este CV: http://lattes.cnpq.br/8510726976369443 Possui graduação em Biomedicas pela Universidade Federal de São Paulo (1979), mestrado em Imunologia pela Universidade de São Paulo (1989) e doutorado em Imunologia pela Universidade de São Paulo (1996). Atualmente é Professor Titular da Universidade Federal da Bahia e Pesquisador Titular do Instituto Gonçalo Moniz, FIOCRUZ-Bahia.Exerece o mandato da presidência da Sociedade Brasileira de Imunologia no biênio 2018-2019. Tem experiência na área de Imunologia, com ênfase em Imunoparasitologia, atuando principalmente nos seguintes temas:imunidade inata e adaptativa, imunoregulação, Leishmania amazonensis, Leishmania chagasi, Leishmania braziliensis . (Texto informado pelo autor)
CRISTINA RIBEIRO DE BARROS CARDOSO
DANIEL DE CARVALHO
Dr. De Carvalho is a renowned expert in cancer epigenomics and leads a research group at the Princess Margaret Cancer Centre and the University of Toronto. He is a pioneer in the use of cancer epigenetics combined with advanced computational approaches for developing novel liquid biopsy tools applied to cancer early detection, classification and monitoring therapy response. Dr. De Carvalho have published over 70 high profile research papers, many of those featured in prestigious scientific journals such as Nature, Science, Cell, Nature Medicine, Cancer Cell among others and was an invited speaker to over 120 talks worldwide, including such prestigious venues as the Opening plenary lecture at AACR annual meeting. For his scientific contributions, Dr. De Carvalho received numerous awards including the Canadian Cancer Society Bernard and Francine Dorval Prize, Canadian Institutes of Health Research (CIHR) Early Career Award in Cancer. He received the Canada Research Chair in Cancer Epigenetics, the Helen M Cooke Endowed Professorship and was elected membership in the 2019 cohort of The Royal Society of Canada. Most recently, Dr. De Carvalho founded and serves as CSO of Adela, a biotech company developing cell-free DNA methylation liquid biopsy technology for cancer early detection, classification and monitoring therapy response”.
Endereço para acessar este CV: http://lattes.cnpq.br/1218389465274602 Possui graduação em Ciências Biológicas pela Universidade Federal de Minas Gerais (2002). É doutor em Ciências Biológicas (Microbiologia-ênfase em Virologia) pela Universidade Federal de Minas Gerais. Fez pós-doutorado no Imperial College London (2007-2009) tendo como principal interesse sensores de DNA da imunidade inata e o estudo da evasão do sistema imune pelo vírus Vaccinia. Foi pós-doutorando no departamento de Bioquímica e Imunologia da UFMG pesquisando as interações patógeno/hospedeiro na infecção por Dengue.Desde 2010, é Professor Adjunto de Imunologia no Departamento de Microbiologia, Imunologia e Parasitologia (MIP) na Universidade Federal de Santa Catarina. Tem como principal área de atuação a imunidade célula-intrísica e interação vírus-hospedeiro. (Texto informado pelo autor)
DARIO S. ZAMBONI
HENRIQUE BORGES DA SILVA
Henrique Borges da Silva is a Brazilian Immunologist. He has completed his Bachelor degree in Biology from the Univ. Sao Paulo (2005) and completed his PhD in Immunology in the same institution in 2014. Between 2015 and 2020 Dr. Borges da Silva was a postdoctoral fellow at Dr. Steve Jameson’s lab at the University of Minnesota. Currently, Dr. Borges da Silva is an Assistant Professor at the Mayo Clinic Department of Immunology (Arizona). Through work in his laboratory, Dr. Borges da Silva aims to understand how extracellular nucleotides regulate the immune system. Nucleotides are produced by and influence numerous intracellular pathways. In diverse circumstances, however, nucleotides are released into the extracellular environment and are sensed by specific receptors called purinergic receptors. Immune cells are not devoid of this process; many purinergic receptors are expressed by the immune system. The main focus of Dr. Borges da Silva is determining how one of these nucleotides, extracellular ATP (eATP), affects transcriptional, metabolic and functional mechanisms of CD8+ T cells in response to viral infections and cancer. This stems from fundamental discoveries made by Dr. Borges da Silva that showed a crucial role for the eATP purinergic receptor P2RX7 in the establishment of CD8-positive T cell memory.
Jean-Luc Imler, obtained his MSc degree from AgroParisTech in Paris in 1985 and his PhD from Strasbourg university in 1988. He then joined the DNAX Research Institute in Palo Alto, CA, to work on cytokines for his post-doctoral training. Returning to France in 1992, he first worked as a research scientist in the biotech company Transgene, before being appointed Professor of cell biology at the University of Strasbourg. J.-L. Imler is chairman of the CNRS Research Unit “Insect Models of Innate Immunity” and director of the Institute of Molecular and Cellular Biology at the University of Strasbourg. J.-L. Imler’s interests have always been on the molecular and cellular aspects of cell signaling, with a focus on the context of host-pathogen interactions. In 1994, he joined as a group leader the Insect immunity Department at CNRS chaired by Jules Hoffmann to work on the model organism drosophila. There, his group first investigated the regulation of antimicrobial peptide expression by Toll receptors, before switching to the regulation of viral infection in insects. J.-L. Imler and his group have shown that viruses are controlled by the mechanism of RNA silencing in drosophila, but also trigger inducible responses, involving the evolutionarily conserved molecule STING.
JOÃO T. MARQUES
JOSÉ CARLOS FARIAS ALVES-FILHO
https://orcid.org/0000-0002-1290-0263 Dr. Cunha graduated in the University of São Paulo at Dario Zamboni’s lab (2012), trained as a post-doctoral fellow at St Jude Children’s Research Hospital with Dr. Douglas Green (2014-2018) and currently holds an Assistant Professor position at University of São Paulo and a Young Investigator from FAPESP. Her laboratory focuses on the cell biology of innate immune cells, working on how signaling transduction cascades initiate, progress and ultimately regulate the function of innate immune cells upon activation of a primary function such as phagocytosis. This knowledge is used to understand the pathogenesis of inflammatory disorders and the balance between resistance and tolerance to infections. She currently investigates the role of the autophagy machinery, a bonafide mechanism of coping with metabolic stresses, in the regulation of phagocytosis and their consequences in innate immune cells.
LUCAS DA SILVA FAUSTINO
LUIS CARLOS DE SOUZA FERREIRA
Luke O’Neill is Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is a world expert on innate immunity and inflammation. His main research interests include Toll-like receptors, Inflammasomes and Immunometabolism. He is listed by Thompson Reuters/ Clarivates in the top 1% of immunologists in the world, based on citations per paper. Professor O'Neill is co-founder of Sitryx, which aims to develop new medicines for inflammatory diseases. Another company he co-founded, Inflazome was recently acquired by Roche. He was awarded the Royal Dublin Society / Irish Times Boyle Medal for scientific excellence, the Royal Irish Academy Gold Medal for Life Sciences, The Society for Leukocyte Biology (SLB) Dolph O. Adams award, the European Federation of Immunology Societies Medal and in 2018 the Milstein Award of the International Cytokine and Interferon Society. He is a member of the Royal Irish Academy, EMBO (European Molecular Biology Organisation) and a Fellow of the Royal Society. Luke also has a passion for communicating science to the public. He has a weekly radio slot on the Pat Kenny show on Newstalk. In 2018 he published with Gill the best-selling ‘Humanology: a scientist’s guide to our amazing existence’ and in 2019 Gill published ‘The Great Irish Science Book’, a Science book for 10-12 year olds. His latest book, also published by Gill is called ‘Never Mind the B#ll*cks Here’s the Science’.
MARCELO TORRES BOZZA
Marco obtained his Bachelor's degree in Biological Sciences in 2009 from the Pontifical Catholic University of Minas Gerais. From 2010 to 2014, Marco developed his master's and doctorate studies, being enrolled in the graduate school of the Biochemistry and Immunology Department at the Federal University of Minas Gerais. Under Prof. Dr. Ricardo Gazzinelli's supervision, he uncovered some molecular and cellular aspects of the innate immune-associated malaria pathogenesis. He has described the importance of the inflammasome activation for the septic shock-like observed during Plasmodium infection. Additionally, one of his doctorate studies unveils the cellular e molecular choreography associated with experimental cerebral malaria. In 2015, Marco started his postdoctoral training by joining the Leukocytes Dynamics lab led by Prof. Dr. Wolfgang Kastenmüller, initially located at the University of Bonn, Germany, and now at the University of Würzburg as part of the Max Planck Research Group – Systems Immunology Institute. Recently, Marco has uncovered an essential piece of the molecular network controlling the CD8+ T cell memory formation. He also has contributed to the development of new insights regarding the immunobiology of invariant T cells. In 2020, Marco returned to Brazil, where he works as a postdoctoral researcher at Prof. Dr. Dario Zamboni at the University of São Paulo Medical School – Ribeirao Preto, exploring cell death dynamics and inflammasome activation in controlling bacterial infections in vivo.
MARCO AURÉLIO RAMIREZ VINOLO
MARIA REGINA D´IMPÉRIO LIMA
PATRÍCIA T. BOZZA
PEDRO M. M. M. VIEIRA
Pedro M M Moraes Vieira is a doctor of veterinary medicine by the University of Brasilia and a PhD in immunology by the University of Sao Paulo. Currently he is Associated Professor of Immunology at the University of Campinas and a researcher in the field of immunometabolism. He spent five years (2011 / 2016) as a Research Fellow at the Division of Metabolism, Endocrinology and Diabetes of the Beth Israel Deaconess Medical Center in Harvard Medical School. During this time, he worked on understanding the link between systemic physiology and macrophage immunometabolic regulation. Prof. Moraes-Vieira is the head of the Laboratory of Immunometabolism. His areas of interest are immunometabolic regulation of tissue resident macrophages in healthy and disease, such as obesity and auto-immune and inflammatory diseases.
SERGIO COSTA OLIVEIRA
I am a Full Professor of Immunology at the Federal University of Minas Gerais, Brazil and my research interest is focused on defining the role of innate immunity and inflammation during the course of the intracellular bacterial infections. I got my PhD and postdoctoral training at the University of Wisconsin-Madison (USA). Currently, I am member of the Brazilian Academy of Science and member of the World Academy of Sciences (TWAS). So far, I have published more than 210 peer-reviewed articles with more than 10,000 citations. Additionally, I have trained 23 Master's and 24 PhD's students, and 39 Post-doctoral fellows. Complete List of Published Work in My Bibliography: http://www.ncbi.nlm.nih.gov/myncbi/sergio.oliveira.1/bibliography/48868768/public/?sort=date&direction=ascending
Tim Sparwasser studied human medicine at the Johannes-Gutenberg-University Mainz and the Ludwig-Maximilians-University Munich (LMU). After his doctorate he continued his research activities at the Institute for Medical Microbiology, Immunology and Hygiene (MIH) at the Technical University of Munich (TUM) and afterwards at the Skirball Institute as Howard Hughes Medical Institute (HHMI) Postdoctoral Fellow in New York. After his habilitation in 2008 he became director of the Institute of Infection Immunology at Twincore (Center for Experimental and Clinical Infection Research) a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research. In 2018, he followed a call from the University of Mainz and became director of the Institute of Medical Microbiology and Hygiene (IMMH) after he had declined a corresponding call from the Technical University of Dresden in 2017. Since 2014 he is a council member of the German Society of Immunology (DGfI). Since 2018, he is a member of the steering committee of the Research Center for Immunotherapy (FZI) at the University of Mainz. In 2019 he was elected as German representative to the Council of the International Union of Immunology Societies (IUIS). The main research interests of his laboratory at the Institute of Medical Microbiology and Hygiene are host-pathogen interactions. Sparwasser was one of the first to recognize that microbial DNA sequences containing specific CpG motifs activate cells of the innate immune system and can therefore be used as adjuvants in experimental vaccination approaches. Using novel genetic models, Sparwasser for the first time directly demonstrated the role of so-called regulatory T cells in the prevention of autoimmunity as well as their importance in the adaptive immune response against tumor cells and various pathogens. Since 2010 Sparwasser has been working on the immune modulatory effects of bacterial metabolites and in particular on the metabolism of immune cells to improve immune responses and vaccinations.
CV: http://lattes.cnpq.br/1527671960187811 Possui graduação em Ciencias Biologicas pela Universidade Federal do Rio de Janeiro (1995), mestrado (1998) e doutorado (2002) pelo Instituto de Biofísica Carlos Chagas Filho, UFRJ e pós-doutorado no Program of Cell Biology do National Jewish Medical and Research Center (Colorado, USA) como bolsista da Pew Latin American Fellows Program in the Biomedical Sciences (2003). Atua em pesquisa no Instituto Gonçalo Moniz e atualmente é coordenadora do Programa de Pós-Graduação em Patologia Humana (PgPAT). Vem se dedicando a estudos na área de parasitologia e biologia da inflamação com ênfase na interação vetor-patógeno-célula hospedeira na infecção por Leishmania sp. (Texto informado pelo autor)